GSK1795091

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

CancerNeoplasms

Phase 1

A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects

CompletedNCT02798978

GlaxoSmithKlineCancer, Neoplasms

Start: 2017-01-10End: 2017-10-13Updated: 2020-11-27

Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

CompletedNCT03447314

GlaxoSmithKlineNeoplasms

Start: 2018-03-26End: 2022-03-11Updated: 2024-09-23

Related Papers

Manufacturing‐dependent change in biological activity of the <scp>TLR4</scp> agonist <scp>GSK1795091</scp> and implications for lipid A analog development

Clinical and Translational Science2022-09-1213 citations

Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study.

2020-07-3018 citations